Stay updated with breaking news from Earlier Lines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First... | May 16, 2023
REGN5459, designed to deplete plasma cells while mitigating the cytokine release syndrome, demonstrated deep and durable clinical responses in heavily pretreated relapsed/refractory myeloma.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The ...